The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice

Cancer Immunology, Immunotherapy

Volumn 60, Issue 7, 2011, Pages 1009-1017

  Gladue, Ronald P ^a   Paradis, Timothy ^a   Cole, Susan H ^a   Donovan, Carol ^a   Nelson, Robin ^a   Alpert, Robbin ^a   Gardner, Joe ^a   Natoli, Ed ^a   Elliott, Eileen ^a   Shepard, Richard ^a   Bedian, Vahe ^a  

^a PFIZER INC   (United States)

Author keywords

CD40; Dendritic cells; IL 12; Immunotherapy; SCID hu

Indexed keywords

CD23 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CISPLATIN; CP 870893; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BREAST TUMOR; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL ACTIVITY; COLON TUMOR; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG BINDING; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; SINGLE DRUG DOSE; T LYMPHOCYTE; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; B-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL;

EID: 79959746703     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1014-6     Document Type: Article

References (29)

1. D Chaudhuri R Suriano A Mittelman RK Tiwari 2009 Targeting the immune system in cancer Curr Pharm Biotechnol 10 166 184 19199949 10.2174/ 138920109787315114 1:CAS:528:DC%2BD1MXkvVSntbw%3D
2. Lustgarten J (2009) Cancer, aging and immunotherapy: lessons learned from animal models. Cancer Immunol Immunother 58:1979-1989
3. R Elgueta MJ Benson VC de Vries A Wasiuk Y Guo RJ Noelle 2009 Molecular mechanism and function of CD40/CD40L engagement in the immune system Immunol Rev 229 152 172 19426221 10.1111/j.1600-065X.2009.00782.x 1:CAS:528: DC%2BD1MXhsFGls7nM
4. L Diehl AT Den Boer EI van der Voort CJ Melief R Offringa RE Toes 2000 The role of CD40 in peripheral T cell tolerance and immunity J Mol Med 78 363 371 11043379 10.1007/s001090000126 1:CAS:528:DC%2BD3cXnsVels7w%3D
5. R Sartorius L D'Apice P Barba, et al. 2003 Induction of human NK cell-mediated cytotoxicity by CD40 triggering on antigen presenting cells Cell Immunol 221 81 88 12747948 10.1016/S0008-8749(03)00060-1 1:CAS:528: DC%2BD3sXjs1eqsro%3D (Pubitemid 36549082)
6. ID Davis Q Chen L Morris, et al. 2006 Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients J Immunother 29 499 511 16971806 10.1097/01.cji.0000211299.29632.8c (Pubitemid 44395275)
7. MF Mackey JR Gunn PP Ting, et al. 1997 Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154 Cancer Res 57 2569 2574 9205055 1:CAS:528:DyaK2sXkt12ltbw%3D (Pubitemid 27283758)
8. K Hanyu T Iida H Shiba T Ohashi Y Eto K Yanaga 2008 Immunogene therapy by adenovirus vector expressing CD40 ligand for metastatic liver cancer in rats Anticancer Res 28 2785 2789 19035311
9. H Dzojic A Loskog TH Totterman M Essand 2006 Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model Prostate 66 831 838 16491482 10.1002/pros.20344 1:CAS:528:DC%2BD28XlsFGmu78%3D
10. RR French HT Chan AL Tutt MJ Glennie 1999 CD40 antibody evokes a cytotoxic T cell response that eradicates lymphoma and bypasses T cell help Nat Med 5 548 553 10229232 10.1038/5505 1:CAS:528:DyaK1MXivVKrs7g%3D (Pubitemid 29068515)
11. RR French VY Taraban GR Crowther, et al. 2007 Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation Blood 109 4810 4815 17311995 10.1182/blood-2006-11-057216 1:CAS:528:DC%2BD2sXmt1Ogur0%3D (Pubitemid 46827776)
12. J Honeychurch MJ Glennie PW Johnson TM Illidge 2003 Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T cell-dependent immunity-B cell lymphoma Blood 102 1449 1457 12714523 10.1182/blood-2002-12-3717 1:CAS:528:DC%2BD3sXmsFWktL4%3D (Pubitemid 36988056)
13. AL Tutt L O'Brien A Hussain GR Crowther RR French MJ Glennie 2002 T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody J Immunol 168 2720 2728 11884438 1:CAS:528:DC%2BD38XitFSktrY%3D (Pubitemid 34211649)
14. SM Todryk AL Tutt MH Green, et al. 2001 CD40 ligation for immunotherapy of solid tumours J Immunol Methods 248 139 147 11223075 10.1016/S0022-1759(00) 00349-5 1:CAS:528:DC%2BD3MXht12nsrw%3D (Pubitemid 32167031)
15. GJ van Mierlo AT den Boer JP Medema, et al. 2002 CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity Proc Natl Acad Sci USA 99 5561 5566 11929985 10.1073/pnas.082107699 (Pubitemid 34411588)
16. L Diehl AT den Boer SP Schoenberger, et al. 1999 CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T lymphocyte tolerance and augments anti-tumor vaccine efficacy Nat Med 5 774 779 10395322 10.1038/10495 1:CAS:528:DyaK1MXksVCrs78%3D (Pubitemid 29318611)
17. RH Vonderheide JP Dutcher JE Anderson, et al. 2001 Phase I study of recombinant human CD40 ligand in cancer patients J Clin Oncol 19 3280 3287 11432896 1:CAS:528:DC%2BD3MXltlShtbg%3D (Pubitemid 32591446)
18. RE Toes SP Schoenberger EI van der Voort R Offringa CJ Melief 1998 CD40-CD40 ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity Semin Immunol 10 443 448 9826577 10.1006/smim.1998.0147 1:STN:280:DyaK1M%2FksFCquw%3D%3D (Pubitemid 28564373)
19. A Hirano DL Longo DD Taub, et al. 1999 Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand Blood 93 2999 3007 10216096 1:CAS:528:DyaK1MXivVyltLY%3D (Pubitemid 29200792)
20. SC Hill SJ Youde S Man, et al. 2005 Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis J Immunol 174 41 50 15611226 1:CAS:528:DC%2BD2cXhtFaiurbP (Pubitemid 40007390)
21. EM Gomes MS Rodrigues AP Phadke, et al. 2009 Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells Clin Cancer Res 15 1317 1325 19228733 10.1158/1078-0432.CCR-08-1360 1:CAS:528:DC%2BD1MXitVOktrY%3D
22. NT Georgopoulos A Merrick N Scott PJ Selby A Melcher LK Trejdosiewicz 2007 CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killing Int J Cancer 121 1373 1381 17534894 10.1002/ijc.22846 1:CAS:528:DC%2BD2sXhtVSmtL%2FE (Pubitemid 47293808)
23. RH Vonderheide MO Butler JF Liu, et al. 2001 CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/86 expression or T cell alloreactivity Int J Oncol 19 791 798 11562757 1:CAS:528:DC%2BD3MXnsFSmu74%3D
24. Frucht DM (2002) IL-23: a cytokine that acts on memory T cells. Sci STKE 114:1-3
25. H Tahara MT Lotze 1995 Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer Gene Ther 2 96 106 7719935 1:CAS:528:DyaK2MXktFyku7w%3D
26. K Tsung JB Meko GR Peplinski YL Tsung JA Norton 1997 IL-12 induces T helper 1-directed antitumor response J Immunol 158 3359 3365 9120294 1:CAS:528:DyaK2sXit1Cksb8%3D (Pubitemid 127484054)
27. N Weerasekera I Hudson 2007 Lessons from TGN-1412: the impact on phase I clinical trials IDrugs 10 230 232 17390240 (Pubitemid 46494432)
28. L Biancone V Cantaluppi M Boccellino, et al. 1999 Activation of CD40 favors the growth and vascularization of Kaposi's sarcoma J Immunol 163 6201 6208 10570312 1:CAS:528:DyaK1MXns12rt7s%3D
29. RH Vonderheide KT Flaherty M Khalil, et al. 2007 Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody J Clin Oncol 25 876 883 17327609 10.1200/JCO.2006.08.3311 1:CAS:528:DC%2BD2sXjvVKmtLk%3D (Pubitemid 350002889)